Transcranial Ultrasound in Clinical SONothrombolysis
- Conditions
- Acute Ischemic Stroke
- Registration Number
- NCT00504842
- Lead Sponsor
- ImaRx Therapeutics
- Brief Summary
This is a randomized, placebo controlled, parallel group dose escalation trial to evaluate the safety, tolerability, and activity of four sequential dose tiers of MRX-801 and ultrasound as an adjunctive therapy to tissue plasminogen activator (tPA) treatment in subjects with acute ischemic stroke.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 72
- Acute ischemic stroke
- Occlusion demonstrated by transcranial Doppler ultrasound
- Eligible for tPA
- Right to left cardiac shunt
- Moderate to severe COPD
- Uncontrolled hypertension
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Incidence of symptomatic intracranial hemorrhage 36 hours
- Secondary Outcome Measures
Name Time Method Rate of recanalization of occluded artery 120 minutes Independent outcome (modified Rankin Scale 0-2) 90 days
Trial Locations
- Locations (14)
University of Alabama
🇺🇸Birmingham, Alabama, United States
Barrow Neurology Clinics at St. Joseph's Hospital
🇺🇸Phoenix, Arizona, United States
Hoag Memorial Hospital
🇺🇸Newport Beach, California, United States
California Pacific Medical Center
🇺🇸San Francisco, California, United States
Colorado Neurological Institute
🇺🇸Englewood, Colorado, United States
Christiana Care Health System
🇺🇸Newark, Delaware, United States
University of Miami
🇺🇸Miami, Florida, United States
St. Louis University School of Medicine
🇺🇸St. Louis, Missouri, United States
University of Rochester
🇺🇸Rochester, New York, United States
Lehigh Valley Hospital
🇺🇸Allentown, Pennsylvania, United States
Scroll for more (4 remaining)University of Alabama🇺🇸Birmingham, Alabama, United States